Kaplan Fox Encourages Investors of Endava plc (NYSE: DAVA) to Contact the Firm Before Lead Plaintiff Deadline on November 30, 2026

A securities class action alleges Endava misled investors about its accounting treatment of certain customer and supplier agreements. The complaint says CFO Mark Thurston was placed on administrative leave on September 21, 2026, amid an internal investigation into those matters; Endava ADSs fell $0.68, or over 24%, to $2.11 on September 22. The proposed class’s lead-plaintiff deadline is November 30, 2026.

Analysis

The key risk is not the class-action filing itself, but whether the internal review finds that customer/supplier arrangements changed revenue recognition, reported margins, or cash conversion. If so, investors may need to discount not only historical results but also management credibility and the reliability of forward guidance; the size of that discount depends on the accounting scope, not the allegations alone. The reported 24% one-day decline has already repriced the headline risk, so an unhedged short now has meaningful squeeze risk if the review is narrow or the allegations prove unsupported.

Over days, expect event-driven volatility and procedural noise; the November 30 lead-plaintiff deadline is not a merits catalyst. Over 1–3 months, the decision-useful catalysts are the investigation’s findings, any auditor or filing developments, and quantified effects on revenue, margins, receivables, and cash flow. Over 6–18 months, even absent a material restatement, weakened customer confidence could lengthen sales cycles or create openings for larger IT-services competitors such as Accenture and Cognizant; that is a conditional channel, not evidence of customer losses. The thesis weakens if the company promptly substantiates its accounting, maintains filings and guidance, and shows no material cash-collection or contract impact. The article provides no financial-impact estimate, so avoid treating the complaint’s allegations as established fact.

Key Decisions for Investors

• Do not add an outright short solely on the lawsuit after the sharp repricing. Keep DAVA on an event-risk watchlist and size any existing exposure for a further gap move in either direction.
• Wait for primary disclosures before taking directional risk: verify the investigation’s scope, auditor involvement, any filing delay or restatement, and quantified effects on revenue, operating results, receivables, and operating cash flow.
• If volatility and option liquidity support it, consider a defined-risk bearish options structure rather than naked short exposure, but only after reviewing implied volatility and upcoming disclosure timing; the supplied data do not establish attractive pricing.
• Reassess the thesis if findings indicate no material accounting impact and guidance remains intact; strengthen it only with evidence such as a material restatement, delayed filings, auditor concerns, or deterioration in cash conversion.